Skip to main content

Table 1 Baseline characteristics of 204 patients

From: Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

Characteristics

Group A (n = 120)

Group B (n = 84)

P value

Age, years, mean ± SD

37.6 ± 8.0

36.9 ± 10.1

0.289

Male gender

70 (58.3%)

53 (63.1%)

0.561

Body weight, Kgs, mean ± SD

54.3 ± 10.3

56.1 ± 13.8

0.766

Previous major OIs

41 (34.2%)

11 (13.1%)

0.001

Baseline hemoglobin, mg/dl, median (IQR)

10.7 (8.4–12.0)

11.5 (9.5–13.3)

0.035

Baseline CD4, cell/mm3, median(IQR)

6 (16–29)

139 (92–198)

<0.001

Baseline CD4%, median (IQR)

2 (1–2)

8 (0–13)

<0.001

Baseline plasma HIV RNA, copies/ml, median (IQR)

357,000 (187,000–727,750)

231,000 (69,750–645,250)

0.027

Baseline ALP, U/I, median (IQR)

91.0 (71.0–128.0)

74.5 (58.0–94.2)

<0.001

Baseline ALT, U/I, median (IQR)

32.0 (18.0–50.0)

21.5 (16.0–33.5)

0.003

Baseline total bilirubin, mg/dL, median (IQR)

0.5 (0.4–0.7)

0.5 (0.4–0.7)

0.532